CNAT yes 28% is not bad although considering the 85% stock turnover it has ways to go in my opinion. Its striking that so many shares were available and not in strong hands....meaning lack of institutional participation prior to yesterday. Hopefully institutions picked up a good chunk yesterday. Dew...why is it that biopsys were not done to measure efficacy...or if there is another way to determine it. Are they going to start phase 3 based on surrogate markers endpoints? Will FDA approve such a trial?
Market Data 
Markets 
AI
